Phathom Pharmaceuticals, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $74.3M | $58.3M | $57.6M | $49.5M | $39.5M | $28.5M | $29.7M | $16.4M |
| Cost of Revenue | $15.1M | $12.0M | $7.6M | $6.2M | $5.0M | $3.7M | $3.8M | $2.4M |
| Gross Profit | $59.2M | $46.3M | $49.9M | $43.3M | $34.5M | $24.8M | $25.8M | $14.0M |
| Gross Margin | 79.7% | 79.4% | 86.7% | 87.5% | 87.2% | 86.9% | 87.1% | 85.6% |
| Operating Expenses | ||||||||
| Research & Development | $7.8M | $7.8M | $7.5M | $7.0M | $9.1M | $9.2M | $8.6M | $8.7M |
| SG&A Expense | $55.3M | $54.0M | $48.4M | $51.6M | $85.3M | $94.5M | $76.7M | $76.1M |
| Operating Income | $-4.0M | $-15.5M | $-5.9M | $-15.3M | $-59.9M | $-78.9M | $-59.4M | $-70.8M |
| Operating Margin | -5.3% | -26.5% | -10.3% | -30.8% | -151.7% | -276.5% | -200.3% | -433.0% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-17.6M | $-30.4M | $-21.1M | $-30.0M | $-75.8M | $-94.3M | $-74.5M | $-85.6M |
| Net Margin | -23.7% | -52.1% | -36.7% | -60.5% | -191.9% | -330.7% | -251.0% | -523.3% |
| EPS (Basic) | $-0.21 | $-0.37 | $-0.26 | $-0.41 | $-1.05 | $-1.31 | $-0.99 | $-1.32 |
| EPS (Diluted) | $-0.21 | $-0.37 | $-0.26 | $-0.41 | $-1.05 | $-1.31 | $-0.99 | $-1.32 |
| Shares Outstanding (Basic) | 83.7M | 82.1M | 72.9M | 73.4M | 72.5M | 72.0M | 63.2M | 64.6M |
| Shares Outstanding (Diluted) | 83.7M | 82.1M | 72.9M | 73.4M | 72.5M | 72.0M | 63.2M | 64.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |